DZNE is a research institute for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS, which are associated with dementia, movement disorders and other serious health impairments. To date, there are no cures for these diseases, which represent an enormous burden for countless patients, their families and the healthcare system. DZNE is dedicated to the development and translation into practice of novel strategies for prevention, diagnosis, care and treatment. The institute comprises ten sites across Germany and collaborates with universities, university hospitals, research centers and other institutions in Germany and throughout the world.
Many promises of longevity do not hold up to scientific scrutiny. Yet some factors can influence healthy lifespan—if we take a holistic view of the entire body.
The Helmholtz Health Prevention Task Force aims to increase the focus on prevention in healthcare in Germany and around the world. Eleftheria Zeggini, who is leading the initiative, explains their…
The European Medicines Agency (EMA) has now given the green light for the antibody lecanemab. This means that the first causal agent for Alzheimer's disease is on the verge of approval in the EU. We…
What opportunities will arise for medical research and the healthcare system of the future? To discuss this question, researchers from the Helmholtz Association met with decision-makers from science,…
Alzheimer’s dementia is one of the greatest challenges in neurodegeneration. Significant progress in early detection is being advanced at the German Center for Neurodegenerative Diseases (DZNE) in…
Contact
Deutsches Zentrum für Neurodegenerative Erkrankungen
